Kolosis Announces the Appointment of Tim Larsen as Chief Financial Officer
Kolosis BIO announced today the appointment of Tim Larsen as
Menu
Leverage Established GPO and IDN Agreements through MTF.
The Biggest Technologies in biologics delivered to you.
For decades, DBX has been a trusted name in DBM, earning its reputation through years of proven performance in both preclinical animal models and in clinical studies.1
IKON is a 100% allograft matrix from MTF Biologics, designed to align with your goal of optimizing incisions and supporting sternal closure.
A 100% demineralized cortical bone allograft engineered to address the complex demands of sternal fusion.
MTF’s proprietary aseptic processing ensures preservation of key biological matrices and vital matrix proteins.1
Allograft membrane designed to help with optimizing surgical outcomes and reducing complications in poor healing patients.
Kolosis BIO announced today the appointment of Tim Larsen as
Kolosis BIO announced today the appointment of Keely Coughlin as
Expansion will enhance access to a variety of Demineralized Bone